Results 21 to 30 of about 1,634 (161)

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy [PDF]

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +2 more sources

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months [PDF]

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +2 more sources

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis

Frontiers in Pediatrics, 2023
BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Christian Wilson Turalde
exaly   +3 more sources

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Vaccines
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Camino Trobajo-Sanmartín, Manuel Garcia Cenoz, Juan Carlos Muruzábal Torquemada   +2 more
exaly   +3 more sources

Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease.
Sara Jimeno, Adrian Peláez Laderas, Silvina Natalini Martinez   +2 more
exaly   +3 more sources

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study [PDF]

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +2 more sources

The Impact of Nirsevimab on the Transport of Critically Ill Children. [PDF]

Children (Basel)
Purpose: Respiratory syncytial virus-positive bronchiolitis continues to be the main diagnosis prompting transportation in children younger than one year of age. It represents approximately 15–20% of all services performed by a specialized pediatric transport team.
Alejandre C, Pazos E, Gonzalez-Alvarez P, Girona-Alarcón M, Millán N, Rodriguez M, Covas A, Martinez Planas A, Esteban E.   +8 more
europepmc   +4 more sources

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025) [PDF]

Viruses
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the
Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini, Andrea Alba, Stefano Fiocchi, Mauro Vivalda, Giulia Natta, Alessandra Casati, Mariano Manzionna, Simone Rugolotto, Laura Saggioro, Simona Pesce, Maria Scavone, Antonietta Distilo, Vincenza Roseto, Antonino Di Toro, Luca Pierri, Gianfranco Scarpelli, Elvira Bonanno, Lidia Decembrino, Enrico Felici, Camilla Selvatico, Valentina Saracco, Francesco Morrone, Claudio Costantino, Cecilia Nobili, Mario Giuffrè   +32 more
doaj   +2 more sources

Potential Effects on Elderly People From Nirsevimab Use in Infants

Open Respiratory Archives
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
JOSÉ M Eirós, Ivan Sanz-Muñoz
exaly   +3 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Griesmaier Elke, Hock Michaela, Kiechl-Kohlendorfer Ursula   +2 more
exaly   +3 more sources